

Product Data Sheet

AKT-IN-21

Target: Akt; Apoptosis

Pathway: PI3K/Akt/mTOR; Apoptosis

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description	AKT-IN-21 (compound C36) is a potent AKT inhibitor with broad-spectrum cytotoxicity and anticancer activity. AKT-IN-21 also blocks the cell cycle and induces apoptosis of cancer cells by down-regulating the PI3K/AKT pathway ^[1] .
In Vitro	AKT-IN-21 shows anti-proliferation inhibitory activity and cytotoxcity among serval cancer cells, with IC $_{50}$ s of 2.33 μ M (LNCaP), 2.38 μ M (K562), 1.98 μ M (HepG2), 3.95 μ M (LX-2), respectively [1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Yu J, et al. Design, synthesis and bioevaluation of novel prenylated chalcones derivatives as potential antitumor agents. Eur J Pharm Sci. 2024 Jan 1;192:106660.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA